CliffBio
small molecule

SODIUM HEPARIN

HEPARIN SODIUM

Loss of exclusivity—loss of exclusivity
CompanyBaxter Healthcare Corp →See this company's full patent-cliff portfolio

Drug detail

Brand nameSODIUM HEPARIN
Active ingredientHEPARIN SODIUM
Strength1,000 UNITS/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalMarch 1988
Marketing statusDISCN

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.